phospho-EPO Receptor (Tyr485)抗体特异性结合抗原:抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞,通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而,抗体可通过与病毒或**的特异性结合,直接发挥中和病毒的作用。
产物编号xy- 13088R
英文名称phospho-EPO Receptor (Tyr485)
中文名称磷酸化红细胞生成素受体抗体
别 名EPO Receptor (phospho Y485); p-EPO Receptor (phospho Y485); EPOR (phospho Y485); p-EPOR (phospho Y485); erythropoietin receptor; EPO R; EPO Receptor; Erythropoietin receptor precursor; EPOR_HUMAN; MGC138358.
说 明 书100ul
产物类型磷酸化抗体
研究领域心血管 **学 干细胞 细胞膜受体 G蛋白偶联受体 G蛋白信号
抗体来源搁补产产颈迟
克隆类型笔辞濒测肠濒辞苍补濒
phospho-EPO Receptor (Tyr485)抗体交叉反应 Human,
产物应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 ICC=1:100-500 IF=1:100-500 (石蜡切片需做抗原修复)
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量55kDa
细胞定位细胞膜 细胞外基质 分泌型蛋白
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated synthesised phosphopeptide derived from human EPO Receptor around the phosphorylation site of Tyr485:GP(p-Y)SN
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
phospho-EPO Receptor (Tyr485)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产物介绍产补肠办驳谤辞耻苍诲:
The erythropoietin receptor (EPOR) is a member of the cytokine receptor family. There are several isoforms including: EPOR-F (full length), EPOR-S (soluble form), and EPOR-T (truncated form). Upon erythropoietin (EPO) binding, the EPOR activates Jak2 tyrosine kinase which activates different intracellular pathways including: Ras/MAP kinase, phosphatidylinositol 3-kinase and STAT transcription factors. The stimulated EPOR appears to have a role in erythroid cell survival. Defects in the EPOR may produce erythroleukemia and familial erythrocytosis. A functional EPOR is found in the cardiovascular system, including endothelial cells and cardiomyocytes, and data suggest that the EPO/EPO receptor system plays an important role in cardiac function. In animal studies, treatment with EPO during ischemia/reperfusion in the heart has been shown to limit the infarct size and the extent of apoptosis.
Function:
Receptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase. Isoform EPOR-T acts as a dominant-negative receptor of EPOR-mediated signaling.
Subcellular Location:
Cell membrane and Secreted. Secreted and located to the cell surface.
Tissue Specificity:
Erythroid cells and erythroid progenitor cells. Isoform EPOR-F is the most abundant form in EPO-dependent erythroleukemia cells and in late-stage erythroid progenitors. Isoform EPOR-S and isoform EPOR-T are the predominant forms in bone marrow. Isoform EPOR-T is the most abundant from in early-stage erythroid progenitor cells.
Post-translational modifications:
On EPO stimulation, phosphorylated on C-terminal tyrosine residues by JAK2. The phosphotyrosine motifs are also recruitment sites for several SH2-containing proteins and adapter proteins which mediate cell proliferation. Phosphorylation on Tyr-454 is required for PTPN6 interaction, Tyr-426 for PTPN11. Tyr-426 is also required for SOCS3 binding, but Tyr-454/Tyr-456 motif is the preferred binding site.
Ubiquitinated by NOSIP; appears to be either multi-monoubiquitinated or polyubiquitinated. Ubiquitination mediates proliferation and survival of EPO-dependent cells.
DISEASE:
Defects in EPOR are the cause of erythrocytosis familial type 1 (ECYT1) [MIM:133100]. ECYT1 is an autosomal dominant disorder characterized by increased serum red blood cell mass, elevated hemoglobin and hematocrit, hypersensitivity of erythroid progenitors to erythropoietin, erythropoietin low serum levels, and no increase in platelets nor leukocytes. It has a relatively benign course and does not progress to leukemia.
Similarity:
Belongs to the type I cytokine receptor family. Type 1 subfamily.
Contains 1 fibronectin type-III domain.
SWISS:
P19235
Gene ID:
2057
phospho-EPO Receptor (Tyr485)抗体(antibody,
Ab)是由效应B细胞(效应**B细胞)分泌,机体用于抵御外来物质,如病毒,**等抗原,结构呈“驰”字型的球状蛋白质,仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质,均被称作抗原,因此对于抗抗体(能够结合抗体的抗体)来说,抗体本身也是一种抗原物质。
phospho-EPO Receptor (Tyr485)抗体普通抗体重链和轻链的结构
重链结构:普通的**球蛋白具有2条重链(H链),分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型,对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构: 普通**球蛋白具有2条轻链(L链),分子质量约25kDa,有κ链和λ链两种亚型,这两种轻链决定了Ig的亚型类别(IgG1,IgG2,IgG3,IgG4)。一个天然的Ig分子两条轻链总是相同的,但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同,正常人血清**球蛋白κ链:λ链约为2:1,而在小鼠的比例为20:1。
2.2抗体Fab段和Fc段
滨驳骋经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应;经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段(fragment of antigen binding,Fab),相当于抗体分子的两个臂,由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段(fragment crystallizable,Fc)相当于Ig的CH2和CH3结构域,是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区,以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域,相当于Y字结构下面那一部分。
合格 SLC20A2 溶质载体蛋白家族20成员2抗体
合格 Ribonuclease 3/ECP 嗜酸性粒细胞阳离子蛋白抗体
合格 alpha 1 Fetoprotein 甲胎蛋白抗体
合格 NEU1/Neuraminidase 神经氨酸酶1抗体
合格 ZNF154 锌指蛋白154抗体
合格 SWAP70 开关相关蛋白70抗体
合格 Connexin 29 间隙连接蛋白29/GJE1抗体
合格 CBR1 羰基还原酶1抗体
合格 ZNF277 锌指蛋白277抗体
合格 BASP1 脑富含膜附着信号蛋白1抗体
合格 phospho-ZIP Kinase (Thr265) 磷酸化死亡相关蛋白激酶3抗体
合格 BDKRB1 缓激肽B1受体抗体
合格 IFI-202 γ干扰素诱导蛋白202抗体
合格 Ferritin Heavy Chain 铁蛋白重链抗体
合格 p53 (FL-393) 肿瘤抑制基因p53抗体
合格 KCNAB1/Kv beta 1 电压门控钾通道蛋白1抗体
合格 合格 RELL2 **组织表达受体蛋白样蛋白2抗体
合格 合格 PRMT2 蛋白精氨酸甲基转移酶2抗体
合格 SENP7 泛素特异性蛋白酶SENP7抗体
合格 SHC4 SHC4蛋白抗体
合格 SLC19A3 溶质载体家族19成员3抗体
合格 合格 RBKS 核糖激酶RBKS抗体
合格 合格 phospho-IRS1 (Tyr1179) 磷酸化胰岛素受体底物1抗体
合格 ABCB4 ATP结合蛋白家族4抗体
合格 合格 ITCH/AIP4 激活素受体相互作用蛋白4抗体
合格 SLC30A3 溶质载体锌转运3抗体
合格 EIF2S2 真核启动因子2β抗体
合格 BZW2 BZW2蛋白抗体
合格 PIAS1 激活STAT蛋白抑制因子1抗体
合格 合格 YIPF3 自然杀伤细胞特异性抗原YIPF3抗体
合格 USP15 去泛素化酶15抗体
合格 Synaptophysin 突触小泡蛋白P38抗体
合格 HEL308 DNA解旋酶HEL308蛋白抗体
合格 合格 phospho-Smad2/Smad3 (Thr8) 磷酸化细胞信号转导分子SMAD2/SMAD3抗体
合格 合格 CD28 CD28抗体
合格 IP3 receptor 5-三磷酸肌醇受体1抗体